Magdalena Lesisz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Magdalena Lesisz has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Gabriela Olszowy1 shared publication
- Jakub Magdziarz Ibrahim-El-Nur
Department of Social Medicine and Public Health, Medical University of Warsaw, Pawińskiego 3a, 02-106 Warsaw, Poland
1 shared publication - Joanna Rymuza
Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland
1 shared publication - Julia Krzesińska1 shared publication
- Julia Wiktorowska
Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland
1 shared publication - Katarzyna Bochniak
Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 13 January 2026
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 21 (4) , 208-214
Predictive value of thyroid-related biomarkers in Graves’ disease – a systematic review
Graves’ disease is the most common cause of hyperthyroidism and is characterized by a clinical course often difficult to predict. While some patients experience relapses, others achieve long-term remission. It is crucial to improve the accuracy of predicting disease course in order to identify patients who are most likely to benefit from antithyroid drug therapy, thereby avoiding potential complications associated with more radical treatments. The aim of this systematic review is to gather up-to-date knowledge in this field and, based on it, to determine whether commonly available thyroid-related biomarkers can predict the likelihood of remission after antithyroid drug therapy. Thyroid stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4) and TSH-receptor antibodies (TRAb) were evaluated. A total of 964 articles (394 from PubMed and 570 from Embase) were initially identified. After screening and eligibility assessment, 19 studies were included in the final analysis. The results of these studies were heterogenous and partly inconclusive. However, TRAb appears to be the most useful marker in predicting remission. Low baseline TRAb concentrations are associated with a higher probability of remission, while higher values correlate with a more severe clinical course and a greater risk of relapse. The predictive value of FT3 and FT4 as markers is questionable. TSH tends to be the least informative predictor of the outcome. In conclusion, looking at the nature of Graves’ disease, which may be relapsing-remitting, further research in this area is warranted to enhance the quality of life of patients with Graves’ disease.
- 13 January 2026
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 21 (4) , 208-214
Open AccessPredictive value of thyroid-related biomarkers in Graves’ disease – a systematic review
Graves’ disease is the most common cause of hyperthyroidism and is characterized by a clinical course often difficult to predict. While some patients experience relapses, others achieve long-term remission. It is crucial to improve the accuracy of predicting disease course in order to identify patients who are most likely to benefit from antithyroid drug therapy, thereby avoiding potential complications associated with more radical treatments. The aim of this systematic review is to gather up-to-date knowledge in this field and, based on it, to determine whether commonly available thyroid-related biomarkers can predict the likelihood of remission after antithyroid drug therapy. Thyroid stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4) and TSH-receptor antibodies (TRAb) were evaluated. A total of 964 articles (394 from PubMed and 570 from Embase) were initially identified. After screening and eligibility assessment, 19 studies were included in the final analysis. The results of these studies were heterogenous and partly inconclusive. However, TRAb appears to be the most useful marker in predicting remission. Low baseline TRAb concentrations are associated with a higher probability of remission, while higher values correlate with a more severe clinical course and a greater risk of relapse. The predictive value of FT3 and FT4 as markers is questionable. TSH tends to be the least informative predictor of the outcome. In conclusion, looking at the nature of Graves’ disease, which may be relapsing-remitting, further research in this area is warranted to enhance the quality of life of patients with Graves’ disease.
- Open Access
- 29 September 2025
- Published by Institute of Rural Health in Medycyna Ogólna i Nauki o Zdrowiu
- Vol. 31 (3) , 177-184
Demand for Medical Personnel in the era of population aging – Review of International experiences and recommendations
Introduction and objective: Population aging in Poland and Europe poses new challenges for healthcare systems. Strategies are being developed at the international and national levels to counteract the effects of the demographic crisis, including reforms in medical staffing. The purpose of this...
- 29 September 2025
- Published by Institute of Rural Health in Medycyna Ogólna i Nauki o Zdrowiu
- Vol. 31 (3) , 177-184
Open AccessDemand for Medical Personnel in the era of population aging – Review of International experiences and recommendations
Introduction and objective: Population aging in Poland and Europe poses new challenges for healthcare systems. Strategies are being developed at the international and national levels to counteract the effects of the demographic crisis, including reforms in medical staffing. The purpose of this...